Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor.
J Oncol Pharm Pract
; 29(2): 493-497, 2023 Mar.
Article
em En
| MEDLINE
| ID: mdl-35747932
ABSTRACT
CASE REPORT We report the first case of orbital myeloid sarcoma that was successfully treated with a standard venetoclax dose of 25%. A 38-year-old man with acute myeloid leukemia (AML) post-haplo-hematopoietic stem cell transplantation (HSCT) presented with a nine-month history of progressive right proptosis and a visual acuity deficit. The patient was treated with venetoclax (100â
mg orally on days 1-28), cytarabine (40â
mg subcutaneously, days 1-10), and itraconazole (100â
mg twice daily orally on days 1-28). MANAGEMENT AND OUTCOME:
The present case report shows that using cytochrome P450 (CYP) inhibitors is a helpful strategy to reduce the cost of expensive treatments.DISCUSSION:
There are limited data on the use of CYP inhibitors as a strategy to reduce the costs of expensive drugs (i.e. venetoclax). This approach has some advantages over standard dose venetoclax (400â mg/day) such as significantly reduced costs (which is relevant for patients in low-income countries). In this case, we used itraconazole-a potent CYP3A4 inhibitor-which can theoretically reduce the dose to 100â mg/day without losing serum therapeutic concentrations.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Leucemia Mieloide Aguda
/
Sarcoma Mieloide
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article